Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

116 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Which subgroup of patients with rheumatoid arthritis benefits from switching to rituximab versus alternative anti-tumour necrosis factor (TNF) agents after previous failure of an anti-TNF agent?
Finckh A, Ciurea A, Brulhart L, Möller B, Walker UA, Courvoisier D, Kyburz D, Dudler J, Gabay C; Arthritis. Finckh A, et al. Among authors: dudler j. Ann Rheum Dis. 2010 Feb;69(2):387-93. doi: 10.1136/ard.2008.105064. Epub 2009 May 4. Ann Rheum Dis. 2010. PMID: 19416802 Free PMC article.
B cell depletion may be more effective than switching to an alternative anti-tumor necrosis factor agent in rheumatoid arthritis patients with inadequate response to anti-tumor necrosis factor agents.
Finckh A, Ciurea A, Brulhart L, Kyburz D, Möller B, Dehler S, Revaz S, Dudler J, Gabay C; Physicians of the Swiss Clinical Quality Management Program for Rheumatoid Arthritis. Finckh A, et al. Among authors: dudler j. Arthritis Rheum. 2007 May;56(5):1417-23. doi: 10.1002/art.22520. Arthritis Rheum. 2007. PMID: 17469098 Free article.
Do new biologics meet the unmet medical need in rheumatoid arthritis? Safety and efficacy of abatacept following B-cell depletion.
Walker UA, Courvoisier DS, Dudler J, Aeberli D, von Kempis J, Scherer A, Finckh A; Swiss Clinical Quality Management Programme in Rheumatic Diseases. Walker UA, et al. Among authors: dudler j. Rheumatology (Oxford). 2011 Jan;50(1):243-4. doi: 10.1093/rheumatology/keq258. Epub 2010 Aug 17. Rheumatology (Oxford). 2011. PMID: 20716674 Free article. No abstract available.
Safety and efficacy of ocrelizumab in combination with methotrexate in MTX-naive subjects with rheumatoid arthritis: the phase III FILM trial.
Stohl W, Gomez-Reino J, Olech E, Dudler J, Fleischmann RM, Zerbini CA, Ashrafzadeh A, Grzeschik S, Bieraugel R, Green J, Francom S, Dummer W. Stohl W, et al. Among authors: dudler j. Ann Rheum Dis. 2012 Aug;71(8):1289-96. doi: 10.1136/annrheumdis-2011-200706. Epub 2012 Feb 2. Ann Rheum Dis. 2012. PMID: 22307942 Free PMC article. Clinical Trial.
Evolution of radiographic joint damage in rituximab-treated versus TNF-treated rheumatoid arthritis cases with inadequate response to TNF antagonists.
Finckh A, Möller B, Dudler J, Walker UA, Kyburz D, Gabay C; physicians of the Swiss Clinical Quality Management for Rheumatoid Arthritis; physicians of SCQM-RA. Finckh A, et al. Among authors: dudler j. Ann Rheum Dis. 2012 Oct;71(10):1680-5. doi: 10.1136/annrheumdis-2011-201016. Epub 2012 Mar 14. Ann Rheum Dis. 2012. PMID: 22419773 Free PMC article.
Use of abatacept in rheumatoid arthritis.
von Kempis J, Dudler J, Hasler P, Kyburz D, Tyndall A, Zufferey P, Villiger PM. von Kempis J, et al. Among authors: dudler j. Swiss Med Wkly. 2012 May 11;142:w13581. doi: 10.4414/smw.2012.13581. eCollection 2012. Swiss Med Wkly. 2012. PMID: 22581564 Free article. Review.
116 results